The drug treatment of heart failure is influenced by the gender of the patient and of the physician
Imagine being forced to say no to a child crying for more food at supper. Sadly, Margie Fischer doesn’t have to imagine it; that was normal life at her family’s dinner table for years. Her daughter Maggie, now 20, suffers from phenylketonuria (PKU), a genetic disease that means her body can’t tolerate anything more than
Full Post: New drug shows promise for phenylketonuria
While the treatment of heart failure has improved over the past two decades, a new study reported in the European Journal of Heart Failure finds that “the use of evidence-based treatments appears to be imbalanced according to the gender of the patient”.
In particular, the study found
- that female patients were less frequently treated with guideline-recommended medications (such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers ARBs) or beta-blockers)
- and that doses were lower in female than in male patients.
However, the patient’s gender was not the only influence on treatment; so was the gender of the physician. For example, the study demonstrated for the first time that drug treatment is more complete when female physicians are taking care of the patient. Thus, the use of ACE inhibitors or ARBs was significantly lower in female patients treated by a male physician than in male patients treated by either a female or male physician.
Similarly, the dose of ACE inhibitors and ARBs was highest in male patients treated by female physicians and was significantly different from the reverse combination (female patient, male physician). Dosage of beta-blockers was comparable in male patients irrespective of the physician’s gender, whereas female patients treated by a male physician received the lowest doses.
The investigators thus concluded that “male patients with chronic heart failure are more likely to receive evidence-based drug treatment than female”, particular so for the prescription of ACE inhibitors and dosage of beta-blockers.
The study was an evaluation of 1857 consecutive patients treated at the centres in Germany; treatment records involving 829 physicians (65 per cent general practitioners, 27 per cent internists, and 7 per cent cardiologists) were analysed with regard to evidence-based drug treatments to improve survival. Assessment of dosages was calculated as a percentage of averages documented in treatment guidelines for heart failure.
Commenting on the results, the study’s first author Dr Magnus Baumhakel from the University Hospital of the Saarland, Homburg, Germany, said: “The use of evidence-based treatments as described in the latest guidelines has undoubtedly improved the treatment of chronic heart failure. But there is still evidence of a gender imbalance in both patients and physicians. From our results it seems fair to say that the gender of the physician plays an important role in adherence to drug treatment recommendations in chronic heart failure.”
This is one of several recent studies to find gender differences in medical care (and survival) in cardiovascular disease. Many have found that women are treated less intensively than men, especially in the acute phase of the disease.
Long-term gene therapy resulted in improved cardiac function and reversed deterioration of the heart in rats with heart failure, according to a recent study conducted by researchers at Thomas Jefferson University’s Center for Translational Medicine. The study was published online in Circulation . The rats were treated with a gene that generates a peptide called
Full Post: Long-term gene therapy used to reverse heart damage in heart failure
Gender matching between donors and recipients is important to short- and long-term survival in heart transplantation, according to a retrospective study presented at the American Heart Association’s Scientific Sessions 2008. “Heart size would seem to be the most obvious factor; beyond that, no one knows why sex matching is important to transplant survival,” said Eric
Full Post: Gender matching between donors and recipients important to survival in heart transplantation
Adults with severe heart failure see almost three times as many Medicare providers each year compared to a typical beneficiary, according to research presented at the American Heart Association’s Scientific Sessions 2008. An analysis conducted by researchers at the University of Colorado and Scios, Inc. showed that: Adults with severe heart failure see an
Full Post: Adults with severe heart failure have more doctor visits, medications than others on Medicare
A compound designed to prevent chest pains in heart patients has shown promising results in animal studies, say scientists. In the second issue of the British Journal of Pharmacology to be published by Wiley-Blackwell, researchers from the Centre de Recherche Pierre Fabre in France, show that the novel compound F15845 has anti-angina activity and can
Full Post: Novel compound F15845 shows promise for angina
Men and women have about the same in-hospital death rate for heart attack - but women are twice as likely to die if hospitalized for a more severe type of heart attack, according to a report in Circulation: Journal of the American Heart Association. Among patients with ST elevation myocardial infarction (STEMI) in a recent
Full Post: Gender disparity gap in heart attack care still present